Who should not take Pemvidutide?
Documented caution flags for Pemvidutide include mTC / MEN-2 history and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Pemvidutide is limited.
Documented caution flags for Pemvidutide
- MTC / MEN-2 history
- Pancreatitis history
- Severe cardiovascular disease
- Pregnancy / nursing
Reported side effects to weigh
- Nausea (titration steps)
- Diarrhea
- Mild HR increase (glucagon effect)
- Fatigue
References
- Pemvidutide for the treatment of NAFLD/NASH, Phase 1b — Altimmune Phase 1b readout, 2023
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study — Harrison SA et al., Journal of Hepatology, 2025
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis — Noureddin M et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pemvidutide
Last updated 2026-06-15.